Archives

by in
Entry Author Date Location
GTC Biotherapeutics Drug Passes Clinical Milestone, Helping Blaze the Trail for U.S. “Pharming” 02/05/08 Boston
For Logical Therapeutics It’s a New City and a New Approach to Anti-Inflammatory Drugs; For the CEO, It’s a Whole New Career 12/13/07 Boston
Millennium Presents Positive Data for Velcade 12/11/07 Boston
GTC Drug Gets Orphan Status 12/10/07 Boston
Riding the Biomarker Wave: Aveo Snags Eli Lilly Deal 12/05/07 Boston
Vertex Faces Setback in Targeted Cancer Drug Program 11/21/07 Boston
Genzyme Arthritis Treament Approval Delayed 11/13/07 Boston
Acusphere Passes Latest Stress Test, But is Time Running Out? 11/07/07 Boston
Genzyme Rises on Promising Campath Data and (or) Takeover Speculation 10/15/07 Boston
Can ToleRx Escape the Autoimmunity-Drug-Development Deathtrap? 09/28/07 Boston
Targanta Therapeutics Sets IPO Terms—Could Make for Nice Comeback for Firm’s CEO 09/26/07 Boston
FDA Panel Votes in Favor of Biogen’s Tysabri for Crohn’s Disease 08/01/07 Boston
Phase III Trial Yields More Bad News for Genzyme 07/06/07 Boston
Genzyme Arthritis Treatment Misses Goal in Pivotal Trial; Company Will Pursue Alternative Strategy 07/05/07 Boston
Aveo’s Better Mousetraps for Cancer Drugs 06/29/07 Boston
Page 2 of 2 « previous page
    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.